Status:
COMPLETED
ADV-TK Improves Outcome of Recurrent High-Grade Glioma
Lead Sponsor:
Huazhong University of Science and Technology
Collaborating Sponsors:
Beijing Tiantan Hospital
Beijing Chao Yang Hospital
Conditions:
Malignant Glioma of Brain
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery,...
Eligibility Criteria
Inclusion
- Histologically confirmed WHO grades 3 to 4 malignant glioma
- Diagnosed recurrence or progression by clinical or radiological evidence
- Fit for intraarterial infusion and intravenous chemotherapy
- Adequate hepatic, renal, and hematologic function.
- Legal age ≥18 years
- Life expectancy ≥12 weeks
- Eastern Cooperative Oncology Group performance (ECOG) ≥2
- Chemotherapy completion ≥4 weeks prior and recovery from drug induced toxicities.
Exclusion
- Active pregnancy
- Prior gene therapy
- Second primary tumor
- Gravidity, lactation, hypersensitivity to antiviral drugs, immunologic deficit, active uncontrolled infections
- Requiring treatment with warfarin or any other anticoagulants
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00870181
Start Date
January 1 2008
End Date
December 1 2012
Last Update
June 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing YouAn Hospital
Beijing, Beijing Municipality, China, 100069